Lynn Tarkington

Lynn Tarkington, RN, BS, is assistant vice president of Physician and Clinical Services at HealthTrust. She previously served as AVP of the clinical team for SourceTrust. Her background includes 30 years in the healthcare industry, with the focus of her clinical work in cardiovascular diseases. Tarkington previously worked with HCA in the corporate quality department, leading a team of professionals in improving cardiovascular quality across the organization. She is currently pursuing a master’s degree in public health and is a member of the American College of Cardiology, American Heart Association and the American College of Healthcare Executives.

Hand with the stent

ACC 2017: Positive Results for Fully Humanized PCSK9 Drug and Medtronic’s CoreValve

In addition to the reported results of  Abbott Vascular’s bioresorbable stent (which Felix Lee, M.D., will report on separately), five late-breaking trials caught my attention at the American College of Cardiology’s 2017 meeting in Washington, D.C., which will also be of interest to many HealthTrust member facilities. A summary of these studies and the implications […]

Read More

Medical professor using human heart model to teach college class

TCT 2016: Big Crowd Hears Breaking Results from Major Studies

The annual Transcatheter Cardiovascular Therapeutics conference featured scientific presentations that highlighted clinical approaches no better and no worse than the alternatives, although in the ILLUMENATE Pivotal Trial a novel paclitaxel-coated balloon was found to be superior to routine percutaneous transluminal angioplasty (PTA) in patients with peripheral arterial disease. Scientific presentations and educational sessions at this […]

Read More


European Society of Cardiology 2016: Primary Outcomes Hard to Budge in Important Cardiology Studies

Compelling evidence was presented at ESC 2016 supporting the use of implantable cardioverter defibrillators in heart failure patients, continuous positive airway pressure to improve patient quality of life, drug-eluting stents in reducing the need for repeat revascularizations, and stem cell therapy for patients with severe heart enlargement.

Read More